NRX Pharmaceuticals IncNASDAQ:NRXPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3100
- TODAY'S CHANGE (%)0.0200 (1.5504%)
- Bid / Lots1.3000/ 1
- Ask / Lots1.3500/ 50
- Open / Previous Close1.3000 / 1.2900
- Day Range
- 52 Week Range
- Volume75,247
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXP |
|---|---|---|
| 09:32 ET | 1322 | 1.3 |
| 09:39 ET | 800 | 1.2901 |
| 09:48 ET | 250 | 1.32 |
| 09:55 ET | 500 | 1.32 |
| 10:00 ET | 500 | 1.3093 |
| 10:02 ET | 100 | 1.3 |
| 10:04 ET | 342 | 1.3 |
| 10:06 ET | 800 | 1.3183 |
| 10:08 ET | 20953 | 1.33 |
| 10:09 ET | 100 | 1.32 |
| 10:11 ET | 3800 | 1.32 |
| 10:13 ET | 5000 | 1.3 |
| 10:44 ET | 349 | 1.3169 |
| 10:47 ET | 100 | 1.32 |
| 10:58 ET | 100 | 1.32 |
| 11:00 ET | 200 | 1.32 |
| 11:02 ET | 700 | 1.32 |
| 11:03 ET | 200 | 1.32 |
| 11:05 ET | 391 | 1.32 |
| 11:07 ET | 700 | 1.32 |
| 11:12 ET | 100 | 1.315 |
| 11:14 ET | 100 | 1.315 |
| 11:16 ET | 13522 | 1.3 |
| 11:20 ET | 500 | 1.3091 |
| 11:27 ET | 500 | 1.3118 |
| 11:39 ET | 200 | 1.32 |
| 11:54 ET | 300 | 1.31 |
| 11:59 ET | 300 | 1.3062 |
| 12:06 ET | 1147 | 1.31 |
| 12:17 ET | 300 | 1.31 |
| 12:24 ET | 200 | 1.31 |
| 12:30 ET | 7800 | 1.31 |
| 12:32 ET | 3600 | 1.3 |
| 12:39 ET | 100 | 1.31 |
| 12:51 ET | 668 | 1.3 |
| 12:57 ET | 200 | 1.305 |
| 01:00 ET | 3950 | 1.31 |
Nov 26, 2024
Nov 25, 2024
DJ NRX Pharmaceuticals Price Target Maintained With a $19.00/Share by HC Wainwright & Co., from 8:48AM ET on Monday Nov 25, 2024 by Dow Jones
8:48AM ET on Monday Nov 25, 2024 by Dow JonesNRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials", from 8:03AM ET on Monday Nov 25, 2024 by Dow Jones
8:03AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 18, 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer, from 4:05PM ET on Monday Nov 18, 2024 by Dow Jones
4:05PM ET on Monday Nov 18, 2024 by Dow Jones*DJ NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams As Chief Financial Officer >NRXP, from 4:05PM ET on Monday Nov 18, 2024 by Dow Jones
4:05PM ET on Monday Nov 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NRX Pharmaceuticals Inc | 15.6M | -0.8x | --- |
Minerva Neurosciences Inc | 15.0M | -5.2x | --- |
Microbot Medical Inc | 16.5M | -1.2x | --- |
Cognition Therapeutics Inc | 16.5M | -0.4x | --- |
Eom Pharmaceutical Holdings Inc | 16.9M | -3.9x | --- |
Sensei Biotherapeutics Inc | 14.0M | -0.5x | --- |
Company Information
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Contact Information
- Headquarters
- 1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801
- Phone
- 484-254-6134
- Fax
- 302-575-1642
Executives
- Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
- Jonathan Javitt
- Chief Financial Officer
- Michael Abrams
- CMC and Technical Operations Advisor
- Riccardo Panicucci
- Independent Director
- Patrick Flynn
- Independent Director
- Sharon Glied
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-1.69 |
Book Value | $-0.14 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
